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Abstract
Background: There is a robust empirical evidence base supporting the acute efficacy of electroconvulsive
therapy (ECT) for severe and treatment resistant depression. However, a major limitation, probably contributing to
its declining use, is that ECT is associated with impairment in cognition, notably in anterograde and retrograde
memory and executive function. Preclinical and preliminary human data suggests that ketamine, used either as
the sole anaesthetic agent or in addition to other anaesthetics, may reduce or prevent cognitive impairment
following ECT. A putative hypothesis is that ketamine, through antagonising glutamate receptors, protects from
excess excitatory neurotransmitter stimulation during ECT. The primary aim of the ketamine-ECT study is to
investigate whether adjunctive ketamine can attenuate the cognitive impairment caused by ECT. Its secondary
aim is to examine if ketamine increases the speed of clinical improvement with ECT.
Methods/Design: The ketamine ECT study is a multi-site randomised, placebo-controlled, double blind trial. It
was originally planned to recruit 160 moderately to severely depressed patients who had been clinically prescribed
ECT. This recruitment target was subsequently revised to 100 patients due to recruitment difficulties. Patients will be
randomly allocated on a 1:1 basis to receive either adjunctive ketamine or saline in addition to standard anaesthesia for
ECT. The primary neuropsychological outcome measure is anterograde verbal memory (Hopkins Verbal Learning
Test-Revised delayed recall task) after 4 ECT treatments. Secondary cognitive outcomes include verbal fluency,
autobiographical memory, visuospatial memory and digit span. Efficacy is assessed using observer and self-report
efficacy measures of depressive symptomatology. The effects of ECT and ketamine on cortical activity during
cognitive tasks will be studied in a sub-sample using functional near-infrared spectroscopy (fNIRS).
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Discussion: The ketamine-ECT study aims to establish whether or not adjunctive ketamine used together with
standard anaesthesia for ECT will significantly reduce the adverse cognitive effects observed after ECT. Potential
efficacy benefits of increased speed of symptom improvement and a reduction in the number of ECT treatments
required will also be assessed, as will safety and tolerability of adjunctive ketamine. This study will provide
important evidence as to whether adjunctive ketamine is routinely indicated for ECT given for depression in
routine NHS clinical practice.
Trial Registration: Current Controlled Trials: ISRCTN14689382 (assigned 30/07/2012); EudraCT Number: 2011-
005476-41
Keywords: Ketamine, Major Depressive Episode, Electroconvulsive therapy, Memory, Cognition, Efficacy
Background
Depression is a leading cause of disability worldwide
with unipolar depression ranked 9th in the world and 3rd
in Europe amongst causes of health-related disability
2000–2012 [1] and at any one time around 3 % of the
UK population meet the criteria for major depression
[2]. Effective treatment remains a major problem in de-
pression; in the largest study to date examining patient
outcomes in major depression, the STAR*D study, only
a quarter to a third of patients remitted after the first
antidepressant and a about third had still failed to remit
after 4 drug interventions [3].
The National Institute for Health and Clinical Excel-
lence (NICE) recommends electroconvulsive therapy
(ECT) as a treatment option for patients with severe de-
pression that is life threatening or those with moderate or
severe depression who have not responded to multiple
drug treatments and psychological treatment [4]. ECT has
been demonstrated to have greater efficacy than pharma-
cotherapy (effect size, ES -0.8) [5] and achieves remission
rates of about 50 % in patients who have failed to respond
to drug treatments [6]. It has equal efficacy in both uni-
polar and bipolar depressed patients [7].
Despite the robust evidence base demonstrating the
efficacy of ECT, the number of patients being treated
with it has fallen dramatically in recent decades. In
England over a 3 month period in 2006, an estimated
1250 patients received ECT compared with over double
that number in 1999 [8]. The reduction in ECT usage
may be a consequence of concerns about a poor riskbe-
nefit balance due to adverse cognitive side effects [9].
ECT treatment is associated with significant objective
impairments in cognitive function, the largest effect be-
ing on verbal delayed recall, but also with significant
impairment in all tests of anterograde memory, executive
function and processing speed [10]. Following the end of
ECT treatment there is a rapid reversal of deficits, with
moderate to large improvements above baseline in most
measures after 1–2 weeks [10]. However, one study
showed enduring deficits in spatial recognition memory
one month after end of treatment [11]. There is uncer-
tainty as to the magnitude and persistence of retrograde
amnesia following ECT [12], though a systematic review
suggested that 29–55 % of patients reported persistent
and often distressing loss of important past memories
after ECT [13]. It has been reported that there is an associ-
ation between subjective memory impairment and objective
autobiographical memory impairment immediately after
ECT course as well as 6 months later [14]. A survey across
multiple clinical hospitals suggested that the severity, inci-
dence and persistence of memory and cognitive dysfunction
after ECT was related to treatment approach [15].
The precise mechanisms underlying the effects of ECT
are not fully understood, but altered synaptic function-
ing in neural circuits involved in mood and cognition is
thought to play a key role [16]. Glutamate, an amino
acid neurotransmitter with a role in both neuroplasticity
and excitotoxicity, acts on a variety of receptors in the
brain, most commonly N-methyl-d-aspartate (NMDA)
and α-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA) receptors [17]. Preclinical evidence supports
a role for glutamate in mood regulation and in the action
of antidepressant treatments [17, 18]; in particular de-
creased NMDA-mediated, and increased AMPA-mediated
neurotransmission has been proposed [18]. Studies in de-
pressed patients have found decreased frontal cortical mea-
sures of glutamate measured in vivo by magnetic resonance
spectroscopy (MRS) which normalises with effective treat-
ment [17]. There are similar findings with ECT; pre-
treatment glutamate and glutamate-related concentrations
have been found in dorsolateral prefrontal cortex [19] and
anterior cingulate cortex [20, 21] which either normalised
after ECT [19, 21] or predicted treatment response [20].
Glutamate also has a central role in cognition especially
learning and memory, through its role in synaptic plasti-
city and the signalling pathway involved in long-term po-
tentiation in the hippocampus [22]. It has been proposed
that the memory impairment occurring with ECT is a
consequence of indiscriminate activation/saturation of
glutamate receptors at the time of the seizure leading to a
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disruption of hippocampal plasticity involved in memory
[23]. Autobiographical memory impairment may occur
through disruption of the reconsolidation of ‘fragile’ reac-
tivated or recalled memories [24].
Ketamine is a dissociative anaesthetic, analgesic and
psychotomimetic which inhibits NMDA receptors but
also stimulates glutamate release and potentiates activity
at non-NMDA receptors such as AMPA receptors [25].
Recent studies have shown a rapid antidepressant effect
after a single dose of intravenous ketamine alone or as
an adjunct to antidepressants in both unipolar and bipo-
lar depression [26]. Repeated administration maintains
improvement but relapse occurs rapidly on stopping
treatment [27]. Side effects of ketamine treatment in-
clude acute anxiety, increased mood instability, vomit-
ing, and vasovagal episodes, dissociation, dry mouth,
tachycardia and increased blood pressure [27], though
more severe cardiovascular side effects are associated
with higher ketamine doses (0.8–1.0 mg/kg) [26].
Given acutely ketamine can cause cognitive impair-
ment [28], particularly in manipulating information in
working memory and encoding into episodic memory.
However, preliminary human data from retrospective/
non-randomised studies suggested that ketamine anaes-
thesia improves reorientation [29, 30] and word recall
[31] after ECT, and also may result in more rapid clinical
response [32]. Subsequent small randomised controlled
trials (RCTs) have produced mixed results with studies
suggesting impaired reorientation [33, 34] and improved
[35] or unchanged [33] Mini Mental State Examination
(MMSE) scores after ketamine. A further study found
that ketamine augmentation produced no reduction in
cognitive impairment after ultra-brief right unilateral
stimulation on a range of tests [36]; however this tech-
nique is associated with minimal cognitive impairment
compared with standard bilateral ECT which limits in-
terpretation. Two recent meta-analyses looking at effi-
cacy, and including the same 4 placebo-controlled RCTs
in which ketamine has been combined with ECT, have
reached different conclusions. When continuous mea-
sures were pooled a moderate to large advantage for
ketamine was reported early in the ECT treatment
course [26], but no benefit was found when end-of-
treatment response and remission were meta-analysed
[37]. The latter meta-analysis also reported higher rates
of confusion/disorientation/prolonged delirium with
ketamine. At present the small heterogeneous studies of
ketamine augmentation of ECT emphasise the need for
further larger scale trials.
Depression is associated with impaired frontal cortical
metabolism and function [38, 39] and treatment with
antidepressant drugs leads to their normalisation [38,
40]. In contrast ECT is associated acutely with a further
decrease in frontal cortex metabolism [41], and one
hypothesis is that the cognitive deficits seen with ECT
may relate to these frontal effects [42]. If ketamine pre-
vents cognitive deficits with ECT then a test of this hy-
pothesis is whether ketamine prevents ECT-induced
suppression of frontal cortical function.
Aims and Hypotheses
The primary aim of the Ketamine-ECT study is to in-
vestigate the effect of adjunctive ketamine on cognitive
dysfunction caused by ECT using an RCT design with
the hypothesis that ketamine, compared with saline
treatment, given together with standard anaesthesia will
reduce ECT-induced cognitive impairment. Secondary
aims are to 1) investigate the efficacy, tolerability and
acceptability of adjunctive ketamine (we hypothesise
that ketamine treatment will lead to a more rapid im-
provement in depressive symptoms with fewer ECT
treatments needed to achieve remission) and 2) to iden-
tify whether ketamine modifies ECT’s effect on frontal
cortical function using functional near infrared spec-
troscopy (fNIRS) during performance of cognitive tasks.
Methods/Design
Study Design
The Ketamine-ECT study is a randomised, parallel
group, placebo-controlled, double blind trial of ketamine
(0.5 mg/kg), compared to saline, added to standard an-
aesthetic induction, in depressed patients who have been
prescribed ECT. Both participants and researchers will
be blinded to the treatment arm to which patients are al-
located. In the interests of patient safety, the anaesthetic
team will be aware of study treatment allocation, with
this information disclosed to other clinical or research
team members only if safety concerns arise.
Study Population
The study will recruit hospital in-patients and out-
patients with moderate to severe depression who have
been prescribed ECT by their treating psychiatrist and
have been determined fit for ECT and ketamine adminis-
tration by an anaesthetist. All participants will provide
written informed consent. The original aim was to re-
cruit 160 patients, however due to slow recruitment a
revised target of 100 patients, and refinement of the pri-
mary outcome measure, together with a study extension,
was agreed between the study team, Data Monitoring
and Ethics Committee (DMEC) and Trial Steering Com-
mittee (TSC), Research Ethics Committee, the Medicines
and Healthcare products Regulatory Authority (MHRA),
the funder and the sponsor. The recruitment target for a
sub-population drawn from those taking part in the
main RCT to undergo mechanistic studies was originally
100 (revised to 20 due to slow recruitment) together
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with 50 matched healthy volunteers recruited for neuro-
psychological and fNIRS baseline testing comparisons.
Patient Inclusion criteria
 Male or Female aged 18 years and above prescribed
ECT by their treating psychiatrist.
 Current Diagnostic and Statistical Manual of Mental
Disorders-Fourth Edition (DSM-IV) diagnosis of a
major depressive episode, moderate or severe, as
part of unipolar or bipolar disorder, diagnosed using
the Mini International Neuropsychiatric Interview
(MINI) [43].
 American Society of Anesthesiologists score of 1, 2
or stable 3 (excluding mental health considerations
in the scoring), and judged as suitable to receive
ketamine by an anaesthetist.
 Verbal IQ [44] equivalent to 85 or greater and
sufficiently fluent in English to validly complete
neuropsychological testing.
 Capacity to provide written informed consent to
take part in the study.
Patient Exclusion criteria
 DSM-IV diagnosis of a primary psychotic or
schizoaffective disorder, current primary obsessive
compulsive disorder or anorexia nervosa.
 History of drug or alcohol dependence (DSM-IV
criteria) within the last year.
 ECT in last 3 months or has previously received
ECT in the current trial.
 Known hypersensitivity or contraindication to
ketamine or excipients in the injection, including
significant cardiovascular disease, uncontrolled
hypertension, glaucoma, cirrhosis or abnormal liver
function or liver disease.
 Known hypersensitivity or contraindication to
concomitant medications used for ECT including
propofol or suxamethonium or excipients in the
injections.
 Evidence of organic brain disease including
dementia, neurological illness or injury, or medical
illness which may significantly affect
neuropsychological function.
 Detained under the Mental Health Act (1983 as
amended 2007).
 Pregnancy, or at risk of pregnancy and not taking
adequate contraception, breastfeeding.
 Score of less than 24 on the MMSE [45].
Psychotropic medication-free healthy volunteers with-
out a personal or family history of major psychiatric ill-
ness or significant medical illness will also be recruited.
They will be aged over 18 years or over and will be
matched as a group with patients for age and sex.
Recruitment
Patient recruitment was originally planned for 6 NHS
Trusts in the North of England. This was subsequently
increased to 7 Trusts, with 11 ECT suites. Recruitment
for the fNIRS mechanistic sub-study, including healthy
volunteers, will be based in two of the centres where the
equipment will be based (Manchester and Newcastle),
with opportunity to recruit from other sites when prac-
tically feasible to transport the equipment to patients.
Intervention
ECT and anaesthetic treatment protocols will be deter-
mined by the local ECT services but is required to be
consistent with requirements given in the Royal College
of Psychiatrists’ ECT handbook [46]; ECT being given
twice a week. The anaesthetic induction agent of choice
is propofol, with thiopental permissible as an alternative.
For safety reasons etomidate cannot be used to avoid the
potential for an interaction with ketamine excessively
elevating blood pressure. Oral psychotropic medication
continued by the patient’s treating clinical team will re-
main unchanged where possible for at least the first 4
ECT treatments, and ideally until end of ECT. The goal
of ECT is to treat patients to remission (Montgomery-
Åsberg Depression Rating Scale, MADRS ≤10) in ac-
cordance with NICE guidelines [4]. The final decision to
end ECT will rest with the treating clinical team in con-
sultation with the patient and the local ECT treatment
team. Following recruitment, and before their first ECT
treatment, patients will be randomised in a 1:1 ratio to
receive ketamine 0.5 mg/kg or saline as a slow bolus be-
fore the anaesthetic induction agent. Randomisation will
be by permuted block randomisation, stratified by NHS
Trust, carried out by the Manchester Academic Health
Science Centre Clinical Trials Unit (http://www.mahsc-
ctu.co.uk/). Randomisation will occur by telephone and
allocation communicated securely to each Trust Phar-
macy which will securely over-package the study drug to
conceal allocation. On the day of each treatment the an-
aesthetist will open the package and prepare the injec-
tion away from the ECT team and patient to maintain
their blinding. Patients will receive the same allocated
study medication throughout their course of ECT.
Outcome measures
All assessments will be undertaken by trained research
personnel under the supervision of the clinically trained
principle investigators. Figure 1 shows the study sched-
ule for visits and assessments. The primary outcome
time point will be after the fourth ECT treatment.
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Neuropsychological measures
The Hopkins Verbal Learning Test-Revised (HVLT-R)
[47] will be used as the primary outcome measure to as-
sess anterograde memory. Secondary measures are
described in Table 1. The cognitive assessment battery
has been shown in previous research to be sensitive to
the effects of ECT [36] and has been chosen to also be
short enough in duration to be acceptable to patients.
Fig. 1 Flowchart of schedule of visits. fNIRS: function near infrared spectroscopy; MINI: Mini International Neuropsychiatric Interview; Observer
ratings: Breif Psychiatric Rating Scale; Montgomery Åsberg Depression Rating Scale; Clinical Global Impression; Self ratings; EuroQol; Quick
Inventory of Depressive Symptomatology-Self Report
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Clinical efficacy measures
The primary efficacy measure will be change in MADRS
score [48] from baseline with secondary outcomes listed
in Table 1.
Mechanistic measures
Bilateral dorsolateral and ventrolateral prefrontal cortex
response to computerised tasks of verbal fluency (for
category) and working memory (N-Back) will be mea-
sured using fNIRS, a portable brain imaging technique
that can be used at the bedside or in a person’s home.
This uses the differential light absorption properties of
oxyhaemoglobin (HbO) and deoxyhaemoglobin (HbR)
for near infrared light when it passes through the scalp,
skull and superficial layers of the cortex from a light
source placed on the scalp. The change in the light ab-
sorption spectra are measured with detectors placed
nearby also on the scalp. The technique is analogous to
functional magnetic resonance imaging (MRI) using
blood oxygen level dependent changes, although it mea-
sures both HbO and HbR. It is possible to use fNIRS as
a measure of functional changes in cortical blood flow
secondary to neuronal activation [49].
In addition, a spatially resolved spectroscopy tech-
nique will be used, employing a modification of the
diffusion equation of light transport, to provide an ab-
solute measure of tissue oxygenation (the tissue oxy-
genation index). This index is the absolute percentage
of total haemoglobin in the field of view which is oxy-
genated [50]. Its reliability and validity has yet to be
established [51], however it does provide a potential ab-
solute measure with which to assess cerebral tissue me-
tabolism across groups and within subjects [52].
Two purpose built optical tomography systems (Bio-
medical Optics Research Laboratory, Dept. of Medical
Physics and Bioengineering, University College London)
provide a 48 channel array for topographical coverage of
bilateral dorsolateral and ventrolateral prefrontal cortices.
Originally it had been planned to undertake glutam-
ate magnetic resonance spectroscopy and structural
and functional MRI in a subgroup, but this had to be
halted when it became clear that insufficient patients
would be recruited to allow valid analysis.
Sample size, power and effect size
Original sample size and power calculation
Across the 6 NHS Trusts originally involved in the
study, 355 patients received ECT over a 12 month
period in 2009/10, the most recent period available when
planning the study. The most comparable recent study
in the UK [53] found that 41 % of patients receiving
ECT were eligible, using similar inclusion/exclusion cri-
teria to ours, and 18 % were randomised (to either ECT
or transcranial magnetic stimulation). Given the current
study offers adjunctive, rather than alternative treatment,
a 22.5 % recruitment rate was predicted. Based on these
Table 1 Description of neuropsychological and clinical efficacy outcome measures
Abbreviation Full Name Description Reference
Neuropsychological
Measures
HVLT-R Hopkins Verbal Learning Test – Revised Anterograde verbal learning and memory assessment [47]
AMI-SF Autobiographical Memory Inventory – Short
Form
Retrograde assessment of personal memories [59]
COWAT – letter and
category
Controlled Oral Word Association Test Letter and Category fluency assessment [60]
MCG – Complex Figure
Test
Medical College of Georgia Complex Figure Test Anterograde visuospatial memory assessment [61]
Digit Span Digit Span Working memory assessment [62]
GSE-My Global Self-Evaluation of Memory Self-reported assessment of memory [63]




MADRS Montgomery-Åsberg Depression Rating Scale Observer-rated assessment of depressive symptoms [48]
CAS Clinical Anxiety Scale Observer-rated assessment of anxiety symptoms [65]
BPRS Brief Psychiatric Rating Scale Observer-rated assessment of psychiatric symptoms [66]
CGI-S, CGI-I Clinical Global Impression – Severity and
Improvement
Observer-rated global measure of illness severity and
improvement
[67]
QIDS-SR Quick Inventory Depressive Symptomology –
Self Rated
Self-rated measure of depressive symptoms [68]
EQ-5D EuroQol Self-rated measure of health-related quality of life [69]
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figures recruitment of 160 patients over a 24 month re-
cruitment period was forecast as feasible, providing 152
patients for primary end point assuming 95 % of patients
can be assessed after 4 treatments.
The power calculation was based on a clinically use-
ful benefit of a moderate standardised effect size (ES)
for the ketamine-saline difference (0.5–0.6). With a
90 % power, and two-sided p = 0.05, based on inde-
pendent t-tests, we would have been able to detect a
standardised ES of 0.51 for full Intention-To-Treat
(ITT) and 0.54 for a single primary cognitive outcome
based on completer assessments. Using a Bonferroni
correction for the originally proposed three measures
for the primary cognitive outcome, HVLT-R, COWAT
category and AMI-SF (i.e., assuming independence)
gives an 80 % power to detect a standardised ES of 0.51
given a two-sided, corrected, p = 0.05 for each measure.
The study aimed to recruit 100 patients (50 per treat-
ment group) and 50 matched healthy controls to the
mechanistic studies. This would have an 80 % power to
detect an ES of 0.5 with a two-sided alpha level of 0.05
between groups and an ES of 0.57 with a two-sided
alpha level of 0.05 between treatment arms. A previous
fNIRS study in depressed patients [54] found an ES dif-
ference from controls of 0.8 in frontal cortex HbO re-
sponse to a verbal fluency task.
Revised Power calculations
Following initial slow recruitment, the revised recruit-
ment target was adjusted to 100 patients with 95 reach-
ing the primary outcome measure point and the primary
outcome was changed to the HVLT-R alone. This sam-
ple size provides 80 % power to detect an ES of 0.57
(ITT) and 0.58 (completer), two-sided p = 0.05. The tar-
get for recruitment to the mechanistic studies was de-
creased to a sample size of 20 patients (10 per treatment
arm) and 50 controls. This has only a 21 % power to de-
tect an ES of 0.6 with a two-sided p = 0.05 between the
two treatment arms (10 per arm). Comparing 20 patients
and 50 controls will give an ability to detect an ES of 0.6
between groups with 60 % power and two-sided p = 0.05,
and a 70 % power to detect the same size of effect of
ECT itself with a two-side p = 0.05.
Statistical Analysis
Neuropsychological and clinical outcomes
There are no interim analyses planned unless requested
for safety reasons by the DMEC. All estimates of efficacy
will be based on a modified intention to treat (ITT) ana-
lysis including patients who have received at least one
ECT treatment (given that this is a study of the effect of
ketamine on ECT). The main statistical inference for
both neuropsychological and efficacy outcomes will be
made after 4 ECT sessions. In addition, the two
treatment groups will be compared at the end of acute
ECT treatment and 1 and 4 months later. Analysis
methods are specified in a detailed Statistical Analysis
Plan approved by the DMEC and TSC (available on re-
quest). Briefly, for neuropsychological data cross-sectional
analysis of covariance (ANCOVA) models (allowing for
stratifying variables, age, sex, baseline degree of treatment
resistance, electrode placement [bilateral or unilateral]
and baseline values of the outcome being studied) will be
used to evaluate the effects of treatment allocation. The
sensitivity of the findings to missing data will be assessed
with inverse probability weighting adjustments. All ana-
lyses will involve the use of robust standard errors and as-
sociated confidence intervals (allowing for non-normality
and constraints in the ranges of some of the cognitive
outcomes). Efficacy data will be analysed using a ran-
dom effects (random intercepts) ANCOVA model with
time (in weeks) as a quantitative explanatory variable.
The baseline variables will be the same as those for
neuropsychological data. An interaction term between
time and treatment allocation will also be included to
assess the treatment effect.
Mechanistic outcomes
fNIRS data will be preprocessed with HOMER2 (http://
www.nmr.mgh.harvard.edu/PMI/resources/homer2/
home.htm) converting them into HbO and HbR con-
centration changes after noise and motion artefact cor-
rection [55]. Primary analysis will be the region of
interest (ROI) covering the key frontal cortical area and
consist of the anterior optical channels. Channels will
be discarded for very low optical intensity or high mo-
tion artefact according to standard protocols. Stimulus
blocks will be averaged and the maximum haemo-
dynamic changes determined for both HbO and HbR
concentration in a time window based on the expected
peak latency of the haemodynamic response. Repeated
measures analysis of variance will be performed to
compare patients and healthy controls and the effect of
ECT and treatment allocation in patients, assigning 0
values to the missing channels within the ROI.
Status of the Study
The study was registered on 30/07/2012 (ISRCTN14
689382) under the public title “Ketamine ECT study”.
Clinical Trial Authorisation was given by the Medicines
and Healthcare products Regulatory Agency (MHRA:
EudraCT: 2011-005476-41). Ethical approval was granted
by the North West-Liverpool East Research Ethics Com-
mittee (REC Ref No. 12/NW/0021) on 25/01/2012. Re-
cruitment commenced in December 2012 and an extension
to the study and to recruitment was granted by the funder
in 2014, with the study finishing in late 2015.
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Discussion
The Ketamine ECT study will be one of the largest (even
after the reduction in the recruitment target), and one of
the very few multicentre, RCTs investigating ECT prac-
tice that has been conducted in the UK for decades. Pre-
vious research has been inconclusive about whether or
not there is a benefit from augmenting ECT with keta-
mine, both in terms of reducing cognitive impairment,
and improving symptomatic outcome or rate of im-
provement (see Background), and a prospective RCT is
required to determine whether this is clinically useful
and safe, particularly given some evidence that ketamine
might increase the post-treatment recovery time follow-
ing ECT [37], and the limited information about the
risks of repeated ketamine administration in this setting.
Further, no trial to date has assessed the neurocognitive
effects of augmenting bitemporal ECT with ketamine.
The recognised problem of cognitive impairment with
ECT is one of the reasons why it is increasingly being re-
served for only the very severest cases of depression, and
possibly for an older non-working population, in spite of
its efficacy [9]. The numbers of patients receiving ECT
in England and Wales has decreased from approximately
20,000 a year in the 1980s [56] to under 5000 in 2006
[8]. The Scottish ECT Audit Network also shows a con-
tinuing gradual decline between 2006 and 2013 [57]. If
ketamine augmentation can significantly reduce the cog-
nitive impact of ECT, and it is adopted as a standard
treatment, this may lead to a re-evaluation of the risk-
benefit balance for ECT and potentially make it more ac-
cessible to a wider range of patients. A major problem in
the treatment of depression is the limited efficacy of
current treatments, particularly after insufficient re-
sponse to initial therapy. This has been highlighted
most strikingly by the STAR*D study in the United
States [3] which showed that only a quarter to a third
of patients remit with initial treatment, and that remis-
sion rates fall to a seventh in patient who have failed
two or more treatments. ECT is now only used infre-
quently in this situation in spite of evidence that two
thirds of treatment-resistant depressed patients have a
good clinical response, and nearly half remit [6, 57].
Protection against the cognitive adverse effects of ECT
would potentially make it a more acceptable and ac-
cessible therapeutic option for treatment resistant pa-
tients. In addition if speed of response is greater with
ketamine augmentation, this could reduce the number
of ECT treatments required, not only potentially redu-
cing the cognitive impact of treatment, but also making
ECT more cost-effective.
RCTs involving ECT face a number of methodological
challenges. One difficulty in the assessment and analysis
of ECT trials is the lack of a defined number of treat-
ments making up a course of ECT. Some patients
respond very rapidly and need only a few treatments,
others require prolonged courses. In addition it is not
uncommon for individual treatments in a course to be
missed due to patient or timetabling factors. Unlike drug
treatments, ECT is not normally continued past the
point of clinical remission, so that assigning a particular
time period, or number of ECTs, for an end of treatment
assessment is problematic. The solution adopted in this
study is to make the primary assessment point after 4
ECT treatments received. Clinical experience suggests
that most patients receive at least 4 treatments (unless
they drop out due to adverse effects); at this point cogni-
tive effects of ECT are apparent [58] and most patients
will have shown some, if not full, improvement. An ef-
fect of ketamine in reducing cognitive impairment, and
increasing antidepressant effect, should be detectable at
this time point. Secondary time point assessment will at-
tempt to capture the effects at end of ECT and in follow
up. The assessment of the cognitive impact of ECT is
also challenging as cognitive impairments rapidly im-
prove in the period of time following the last ECT treat-
ment [10]. This means that there is a relatively narrow
window of opportunity to assess any cognitive changes.
Having the primary endpoint during the course of ECT
is helpful in this regard as it constrains the window of
assessment to 1-3 days after a treatment.
From the outset, recruitment to the study was antici-
pated to be challenging due to the narrow recruitment
window between the decision to have ECT and the first
treatment. In practice recruitment was further reduced
by two additional factors. First, the number of patients
receiving ECT has been decreasing so that the need to
ensure a large enough pool from which to recruit has
meant involving a large number of Trusts and ECT
suites, each with their own procedural and governance
requirements. Additionally, during set-up and the study
itself, three ECT suites have closed due to NHS Trust
reorganisations, requiring the identification of new sites.
The delayed initiation of these new sites reduced cap-
acity and available time to reach full recruitment. Sec-
ond, the decrease in ECT prescribing has been
combined with a trend to treat, on average, more se-
verely ill patients, a higher proportion of whom than ex-
pected are ineligible for the study due to detention
under the Mental Health Act or lack of capacity to con-
sent. This has restricted our rate of recruitment, never-
theless, the revised recruitment target will still provide
power to identify a clinically important effect size on a
key cognitive measure, anterograde verbal memory mea-
sured by the HVLT-R.
With regard to the mechanistic studies, recruitment has
been especially difficult because the clinical sites are more
geographically scattered than originally planned, severely
limiting the numbers of patients sufficiently close to the
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two imaging centres for MR imaging. It has raised prac-
tical difficulties in transporting the optical imaging equip-
ment for the fNIRS assessments and in being able to do
the testing before the first ECT session. In addition the se-
verity of illness of the patients has meant that many are
reluctant to undergo additional testing above the neuro-
psychological and efficacy assessments. This has meant
having to discontinue the MR imaging and to severely
curtail the recruitment numbers for fNIRS. Nevertheless
we will be able to assess the feasibility and usefulness of
fNIRS in this population in assessing depression and
measuring and predicting the effects of ECT treatment, al-
though the power to detect effects of ketamine augmenta-
tion will be very low.
In summary this is an important study which has the
potential to alter the practice of ECT and to improve
the risk-benefit balance of ECT for patients who need
to receive it. If successful it may allow wider access to
the most effective known acute treatment for depres-
sion. Unfortunately recruitment difficulties as a conse-
quence of the decline in ECT usage, the severity of the
illness of patients receiving ECT, and the changes in
ECT provision will reduce the power of the study to
provide as definitive an answer as originally planned.
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